The appropriate collection and use of data is central to oncology research, clinical treatment, and coverage and reimbursement decisions. However, to accelerate research and development and improve the quality of care delivery, it is vital for organizations to not only understand how to handle, collect, store, and appropriately disseminate data but also to translate it into actionable information that can help transform healthcare delivery.
To develop a pilot for cross-institution and industry agreement on standardization, our standards working group has specifically focused on the development of and agreement to a standard set of must-measure elements for immuno-oncology assays.
WORKING GROUP MEMBERS
- CO-CHAIR: Anna D. Barker, Ph.D., Co-Director of Complex Adaptive Systems, Director the National Biomarker Development Alliance, Director of the Transformative Healthcare Knowledge Networks, Professor, School of Life Sciences, Arizona State University
- CO-CHAIR: Amy Abernethy, M.D., Ph.D., Chief Medical Officer, Chief Scientific Officer and Senior Vice President, Oncology, Flatiron Health
- David Agus, M.D., Professor of Medicine and Engineering, University of Southern California, Founding Director and CEO, Lawrence J. Ellison Insitute for Transformative Medicine of USC
- Jeff Allen, CEO, Friends of Cancer Research
- Kenneth D. Cole Ph.D., Group Leader, Bioassay Methods Biosystems and Biomaterials Division
- Carolyn Compton M.D., Ph.D., Professor, School of Life Sciences, Arizona State University
- Mike Pellini, M.D., Managing Partner, Section 32
- Eric H. Rubin, M.D., Vice President & Therapeutic Area Head, Oncology Early Development, Merck Research Laboratories
- David Spetzler, M.S., Ph.D., MBA., President and Chief Scientific Officer, Caris Life Sciences